magAssist's extracorporeal ventricular assist device (Extra-VAD) was presented in the 2021 Suzhou New District Science and Technology Innovation Exhibition

On Jul 11th, 2021, Suzhou International Elite Entrepreneurship Week, Suzhou New District Venue Activities, and Suzhou New District Science and Technology Innovation Week has begun. To fully display the achievements of scientific research and innovative technology in the region, Suzhou New District has collected plenty of results from institutes, technology start-ups, and other enterprises from technological, interactive, and experiential aspects of the product. The Results were displayed at the Shishan International Conference Centre from the 11th of July to the 13th of July 2021. 2021 Suzhou New District Science and Technology Innovation Achievement Exhibition contains an Integrated Circuit zone, Medical Device Zone, Low-carbon life Zone, New Generation of Information Technology (NGIT) Zone, High-end equipment manufacture zone, Cultural and creative sales zone, etc. Extra-VAD independently developed by magAssist makes a surprise appearance in the medical device zone.

MoyoAssist Extra-VAD

The product combines the latest generation of computational fluid dynamics and active magnetic levitation technology to provide transitional support when the heart loses its pumping function, aiming to provide excellent blood compatibility and a wide power range (adaptable to different clinical use scenarios) . magAssist has been established for 3 years now, and its product has passed the review of the Clinical Ethics Committee of Wuhan Union Hospital in December 2020 and can be clinically used. This development speed far exceeds that of various European and American companies that have developed such products for more than ten years. And this is the only Extra-VAD product in China and the second in the world.

magAssist has grown into an industry benchmark

magAssist has been established since 2017, after 4 years of rapid development, starting from Short to mid-term transition extracorporeal artificial heart products, committed to creating a new generation of acute and critical scenarios, external life support platform, including Extra-VAD entering clinical, and progresses first in the country, Animal experiments for minimal invasive intervention for artificial hearts has been carried out and has the leading progression in the country.

The ECMO technique is mature and animal experiments have been carried out, aiming to fill the domestic market gap. It is expected that from 2023, magAssist will launch at least one class III medical device product into the clinic every year. magAssist will aim to cover the clinical needs of critical acute extracorporeal life support scenarios, continue to complete the product layout, develop products for different people, different support needs, and different clinical scenarios to serve heart patients in China and throughout the world.